Selenoprotein P (SELENOP) is a major selenoenzyme in plasma and linked to antioxidant properties and possibly to lung cancer; however, supporting evidence is limited. We investigated the association between pre-diagnostic plasma SELENOP concentration and lung cancer risk in a case-control study of 403 cases and 403 individually matched controls nested within the Shanghai Men's Health Study. SELENOP concentration in pre-diagnostic plasma samples was measured by a sandwich enzyme-linked immunosorbent assay. Cases were diagnosed with lung cancer between 2003 and 2010. Multivariate conditional logistic regression was used to estimate odds ratios (OR) and the corresponding 95% confidence intervals (CI) for studying the association between plasma SELENOP concentration and lung cancer risk. Cases had slightly lower plasma SELENOP concentration than controls (4.3 ± 1.2 versus 4.4 ± 1.1 mg/l, P difference = 0.09). However, the multivariate analysis showed no association between plasma SELENOP concentration and lung cancer risk among all participants (OR = 1.08, 95% CI = 0.54-2.14 for quartile 4 versus quartile 1), or by smoking status or tumor aggressiveness. In contrast, although the number of cases was limited, plasma SELENOP concentration was positively associated with lung adenocarcinoma risk (OR = 5.38, 95% CI = 1.89-15.35 for tertile 3 versus tertile 1), but not with squamous cell lung carcinoma (OR = 1.69, 95% CI = 0.43-6.70). Our study of adult men living in selenium non-deficient areas in China provides little support for the inverse association between pre-diagnostic plasma SELENOP concentration and lung cancer risk. Our finding of a positive association with risk of lung adenocarcinoma needs to be interpreted with caution.
Introduction
Current evidence on the effect of selenium on lung cancer prevention is inconclusive (1) (2) (3) . The Nutritional Prevention of Cancer Trial, a selenium supplement trial for the prevention of secondary non-melanoma skin cancer that was conducted in areas in the USA known to have low soil selenium content, found a borderline significant lower risk of lung cancer in a group supplemented with selenium when compared with a placebo after a total follow-up of 6.4 years [hazard ratio (HR) = 0.56, 95% confidence intervals (CI) = 0.31-1.01]. This suggestive protective effect was attenuated after an additional follow-up of 3 years (HR = 0.74, 95% CI = 0.44-1.24) (4, 5) . When the participants were stratified by baseline selenium level, a significant protective effect was observed for those in the lowest tertile of selenium level (HR = 0.42, 95% CI = 0.18-0.96), but not in the middle or highest tertile (6) . In a more recent large trial, the Selenium and Vitamin E Cancer Prevention Trial (SELECT), lung cancer risk did not differ between the placebo and selenium-alone or selenium plus vitamin E-supplemented groups (1, 7) . In Linxian, China, an area known to have high esophageal squamous cell carcinoma prevalence and possibly low micronutrient levels among residents, a supplement trial was conducted to examine the effect of four different combinations of vitamins and minerals, including one combining selenium, vitamin E and β-carotene, on the prevention of esophageal cancer (8) . After 5.25 years of supplementation, no difference was detected in lung cancer mortality between the group supplemented with selenium plus other micronutrients and the other three groups that were not supplemented with selenium (9) . Two meta-analyses reported an inverse association between selenium status and lung cancer risk, with evidence of heterogeneity (2, 3) . A meta-analysis of 14 observational studies on selenium and lung cancer risk reported an inverse association with respect to toenail selenium [relative risk (RR) = 0.46, 95% CI = 0.24-0.87, comparing the highest to the lowest level defined in the original studies], but not for serum selenium (RR = 0.80, 95% CI = 0.58-1.10) or self-reported selenium intake (RR = 1.00, 95% CI = 0.77-1.30) (2) . A subsequent case-control study in Poland reported an inverse association of lung cancer risk with serum selenium level, especially one <60 µg/l (10). Notably, that study population exhibits a lower selenium concentration than that typically observed in the USA and has a larger proportion of individuals with circulating concentrations <70-90 µg/l, the plasma level hypothesized to be required for maximum glutathione peroxidase activity (11, 12) . In contrast, the majority of participants in US studies have a selenium concentration above this level (13) (14) (15) . A recent metaanalysis, including the Polish study, reported an inverse association between selenium status and lung cancer risk, although no dose-response association was reported (3).
Selenoprotein P (SELENOP), the major selenoenzyme in plasma, is expressed in most tissues, including lung, and serves as a selenium carrier (16) (17) (18) . It also exhibits antioxidant properties (19) that may ultimately affect lung carcinogenesis (20) . Furthermore, SELENOP concentration may serve as a measure of selenium intake status, especially for a population in which selenium inadequacy is common (21, 22) , while also serving as a functional measure of selenium in selenium-replete populations (13, 22, 23) . Two previous studies reported an inverse association between SELENOP level and respiratory cancer (24) or lung cancer risk (25) .
Taken together, the current evidence on selenium status and lung cancer risk, which mostly comes from North American and European countries, remains inconclusive. To the best of our knowledge, except for the Linxian trial (8, 9) and one previous study conducted among miners in China (26) , no prospective study has been conducted in a general population in Asia to examine the association between selenium status and lung cancer risk. Using SELENOP concentration as the measurement, a recent study in the southern US states suggested a potential racial difference in whites versus African Americans in the association between SENELOP concentration and lung cancer risk (25) . No study among Asians, however, has been conducted. Within the Shanghai Men's Health Study, we conducted a nested case-control study to investigate the association of lung cancer risk with SELENOP concentration in prospectively collected plasma samples.
Materials and methods

Study population
Participants of this study were selected from a population-based, prospective cohort study of 61 480 men in Shanghai, China (27) . Study participants of the Shanghai Men's Health Study were permanent residents in urban areas of Shanghai, had no history of cancer and were aged 40-74 years at the time of study recruitment between 2002 and 2006. They were recruited through home visits where trained interviewers administered the study questionnaire to collect data on participants' demographics, health conditions, lifestyle and food intakes.
Case ascertainment and selection of controls
To ascertain cancer cases and update the vital status of the study participants, participants' data files were linked to the Shanghai Vital Statistics Registry and Shanghai Cancer Registry databases annually, and in-person visits to participants' homes were made every 2-3 years. Among the participants who provided blood and urine samples at enrollment (N = 55 086), 403 men were diagnosed with lung cancer (International Classification of Diseases, Ninth Revision codes) (28) during follow-up through December 2010. For each case, one control was randomly and individually selected from the participants who were alive and had not been diagnosed with any type of cancer at the time of case diagnosis and matched to cases on age (±2 years), time of blood sample collection (in the morning or afternoon), use of any vitamin supplement (information on specific vitamin supplements was not available) during the week before the baseline interview, time interval between last meal and time of blood collection (≤2 h), date of blood collection (±30 days) and smoking status (current, past or never smokers). All participants provided written informed consent before the baseline interview, and the study protocols were approved by the institutional review boards of Vanderbilt University Medical Center and the Shanghai Cancer Institute.
SELENOP measurement
Using the plasma samples, SELENOP was measured by a sandwich enzyme-linked immunosorbent assay using two monoclonal antibodies that recognize a specific binding site in the N-terminal region of SELENOP, per the protocol we developed previously (13) . The assays were performed in duplicate at Dr. Burk's laboratory at Vanderbilt University. SELENOP concentration (mg/l) was calculated for each sample using a standard curve included in each assay plate. A reference human plasma sample was included in each assay plate to serve as internal controls. We also included quality control samples in the assays, and the interassay and intraassay coefficient of variations were 5.56% and 6.32%, respectively. The matched cases and controls were assayed simultaneously within the same batch. Laboratory staff were blinded to the case-control status of plasma samples and the identity of quality control samples.
Statistical analysis
The characteristics of cases and controls were compared using t-test for continuous variables and χ 2 -test for categorical variables. Using multivariate conditional logistic regression, we estimated the odds ratios (OR) and the corresponding 95% CI for the second, third or fourth quartile of plasma SELENOP concentration compared with the lowest quartile for the overall analysis among all participants. The potential confounders we considered were as follows: smoking history (the number of cigarettes smoked per day, duration of smoking and pack-years), household income, education,
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body mass index CI confidence interval COPD chronic obstructive pulmonary disease GPX3 glutathione peroxidase 3 HR hazard ratio OR odds ratio RR relative risk SELENOP selenoprotein P family history of lung cancer, history of chronic obstructive pulmonary disease (COPD; i.e. any one of emphysema, pulmonary tuberculosis, chronic bronchitis and/or asthma), history of major comorbidity other than cancer (i.e. diabetes, hypertension, coronary heart disease or myocardial infarction, each separately), regular exercise (yes or no), regular tea consumption (yes or no), regular alcohol consumption (yes or no) and body mass index (BMI) status (continuous, quadratic terms or categorical, <23, ≤23 to <25 or ≥25 kg/m 2 ). Because several of these variables (i.e. packyears of smoking, education and history of coronary heart disease) each changed the risk estimates by an additional 10% or more, we included them in the fully adjusted model. Stratified analyses were conducted by smoking status (current, past or never smokers) and BMI status (dichotomized at the median value among controls), given that a U-shaped association with SELENOP concentration was reported (23) . We also conducted analyses stratified by dietary selenium intake by dichotomizing the median intake among controls. Information on tumor histology was available for ~60% of the cases, given that we only used information that was verified by two pathologists using tumor samples. We conducted stratified analyses for squamous cell carcinoma (74 cases) and adenocarcinoma (109 cases), but due to the small number of cases for other specific types, we did not conduct separate analyses for small cell carcinoma (26 cases), adenosquamous carcinoma (15 cases), other histologic subtypes (18 cases) or for 'no specific subtype determined' due to lack of tumor histology information confirmed by two pathologists (161 cases). Lung cancer stage information was only available for 213 cases, and hence, we calculated years from the cancer diagnosis to death in order to indicate tumor aggressiveness, which was dichotomized at 1 year. A total of 87 cases were alive at the time of the last follow-up. Owing to the small sample size of some stratified groups, we estimated OR and the corresponding 95% CIs for the second or third tertile of plasma SELENOP concentration compared with the lowest tertile. Sensitivity analysis was conducted by excluding the cases and their matched controls whose blood was collected within 2 years of their lung cancer diagnosis. All statistical analyses were performed using SAS, version 9.3 (Cary, NC).
Results
In this nested case-control study, cases had a slightly lower SELENOP concentration in their plasma than controls (4.3 ± 1.2 versus 4.4 ± 1.1 mg/l) with borderline statistical significance (P = 0.09) ( Table 1) . Smoking status was matched in this study; ~70% of the cases and controls were current smokers, and only 11% were never smokers at the time of blood collection. The mean pack-years of smoking were longer in cases (38.5 ± 21.6 pack-years) than in controls (27.1 ± 17.3 pack-years). Cases were more likely than controls to have attained higher education, have regularly consumed tea and have a history of comorbidity or COPD. Among those with COPD, chronic bronchitis was the Defined as at least once per week continuously for at least 3 months within the 5 years before the baseline interview.
most common condition (15%), followed by pulmonary tuberculosis (14%). BMI was lower in cases than controls. In terms of diet, total caloric intake was lower among cases than controls. Among controls, SELENOP concentrations were statistically significantly higher in older groups, high income group, regular tea consumers and those with history of coronary heart disease (Supplementary Table 1 , available at Carcinogenesis Online). Overall, there was no association between plasma SELENOP concentration and lung cancer risk; the ORs (95% CI) were 0.95 (0.75-1.22), 0.85 (0.52-1.38) and 1.08 (0.54-2.14) for the second, third and fourth quartiles, respectively, compared with the first quartile of plasma SELENOP concentration, and the P trend was 0.87 (Table 2) , after adjusting for pack-years of smoking, education, history of coronary heart disease, BMI and family history of lung cancer (matching factors included age, date and time of blood draw, vitamin supplement use and smoking status).
When we stratified by smoking status, BMI, tumor aggressiveness or time intervals between blood draw and cancer diagnosis, there were no clear patterns of association between plasma SELENOP concentration and lung cancer risk in each stratum (Table 3 ). Our sensitivity analysis, which was limited to cases diagnosed at least 2 years after blood collection, showed results that were similar to the overall analysis. In addition, when we stratified by lung cancer subtypes, we found that plasma SELENOP concentration was not associated with risk of squamous cell lung carcinoma (Table 3) . However, plasma SELENOP concentration was statistically significantly and positively associated with the risk of lung adenocarcinoma; the ORs (95% CI) were 2.44 (1.03-5.81) and 5.38 (1.89-15.35) for the middle and highest tertiles, respectively, compared with the lowest tertile, with a statistically significant linear trend (P trend = 0.002). When we limited our analysis to cases with histologic types other than adenocarcinoma, there was no statistically significant association (OR = 0.81 and 95% CI = 0.46-1.42 for the highest tertile compared with the lowest; P trend = 0.41). The numbers of cases for other subtypes were small, and therefore, we were not able to conduct stratified analysis for cases who had other than squamous cell lung carcinoma or adenocarcinoma.
In terms of selenium intake from foods, it was not associated with the risk of lung cancer. The adjusted ORs (95% CI) were 1.05 (0.66-1.69), 1.07 (0.64-1.78) and 1.34 (0.77-2.33), for the second, third and fourth quartiles, respectively, compared with the first quartile of selenium intake. When we stratified by dietary intake of selenium, there were no clear patterns of association between plasma SELENOP concentration and lung cancer risk (data not shown). Further, there was modest positive correlation between dietary selenium intake and SELENOP concentration (r Spearman = 0.23, P < 0.0001).
Discussion
Although cases appear to have a slightly lower SELENOP concentration in pre-diagnostic plasma than controls, there was no association between plasma SELENOP concentration and lung cancer risk among adult men in Shanghai after adjusting for pack-years of smoking, education, history of coronary heart disease, BMI and family history of lung cancer along with matching factors. No clear patterns of associations were observed by smoking status, BMI, tumor aggressiveness, dietary selenium intake or time intervals between blood draw and lung cancer diagnosis, except for lung cancer histology. We found a positive association between plasma SELENOP concentration and lung adenocarcinoma risk, which is in contrast to our hypothesis and needs to be interpreted with caution.
Our null finding of the association between SELENOP concentration and lung cancer risk among all participants is inconsistent with two previous studies that reported an inverse association with the risk of lung cancer among African Americans (25) or with the risk of respiratory cancer (24) . In the US study (25) , since smoking status was not one of the matching criteria and was included as a covariate along with pack-years of smoking, residual confounding by smoking is possible, as it is in many other studies of nutrition and lung cancer. Moreover, smoking was more common among African Americans than whites (29) , which further raises the possibility of residual confounding with respect to smoking status in their findings. The US study also included both men and women, whereas our study was limited to men. By gender, SELENOP concentration was reported to be relatively higher among men than women in Denmark (mean 3.35 in men versus 3.10 mg/l in women, P < 0.001) (30) and in the USA (5.7 in men versus 5.2 mg/l in women, P = 0.02) (13) . The SELENOP level in our study in Shanghai was relatively higher than the level typically reported in other areas of China where selenium deficiency is prevalent (22) . In addition, a difference by race is possible, given that, in a previous US study, the inverse association was limited to African Americans, and moreover, African Americans had a lower SELENOP concentration than whites (5.02 in African Americans versus 5.45 mg/l in whites, P < 0.0001) (25) . In addition to potential sex and race differences, our population in Shanghai differs from other populations in North American and European countries in terms of lifestyle factors such as food intake, physical activity patterns and the Table 2 . Association between plasma SELENOP concentration and lung cancer risk Adjusted for pack-years of smoking, education, history of coronary heart disease, BMI (quadratic term) and family history of lung cancer.
use of vitamin supplements and non-steroidal anti-inflammatory drugs. This may have contributed to the discrepant findings from US and Swedish studies (24, 25) . In addition, the majority of participants in the Southern Community Cohort Study were recruited through community clinics where their visits were potentially motivated by underlying medical conditions, which may limit the comparability of our study to the Southern Community Cohort Study and other studies. Our study recruited participants through home visits, regardless of their health conditions, and thus may be more representative of a generally healthy population. For the Swedish study (24) , although lung cancer was classified along with respiratory cancer and was not reported separately, a strong inverse association was reported in an age-matched case-control set (not matched on smoking) for various cancer sites (24) . Conversely, our study is the first to report a null association between plasma SELENOP concentration and lung cancer risk, which warrants further investigation. Our finding of a positive association between plasma SELENOP concentration and risk of lung adenocarcinoma is in contrast to our hypothesis and needs to be interpreted with caution. The previous US study did not find differential associations between SELENOP concentration and lung cancer risk by histology (adenocarcinoma or squamous cell carcinoma) (25) , although squamous cell carcinoma and adenocarcinoma of the lung have been hypothesized to have different etiologies (31, 32) . Previously, similar positive associations between SELENOP and other chronic diseases such as type 2 diabetes and esophageal adenocarcinoma were reported, with a suggestion of SELENOP as a prognostic marker of a disease, rather than a risk factor (33, 34) . Given that we only collected blood samples at baseline and had comparatively short follow-up time in which a relatively small number of lung adenocarcinoma cases accrued, our study has limited ability to further elucidate this association, which needs to be reevaluated in the future and also in other study populations.
There is a modest positive correlation between dietary selenium intake and SELENOP concentration (r Spearman = 0.23, P < 0.0001). The dietary selenium intakes were derived from the food frequency questionnaire using the Chinese Food Composition Tables. Because of a large variation in selenium levels of food across China, the estimate of dietary selenium intake by using food frequency questionnaire and Food Composition Tables may not be very accurate. SELENOP accounts for ~50% of total selenium in plasma, and thus, SELENOP concentration in plasma may serve as a better measurement of selenium intake status than self-reported dietary intake (21, 22) . SELENOP is also considered to reflect the functional status of selenium (13, 23) . Selenoproteins, including SELENOP, are well known for their antioxidant roles, as many catalyze oxidation-reduction reactions using selenocysteine as an active site. SELENOP is also known for its roles in selenium transport. In addition to glutathione peroxidase 3 (GPX3), SELENOP is one of the few secreted selenoproteins and is primarily produced in the liver at the main site of selenium metabolism (17) . In comparison with most selenoproteins that only have one selenocysteine residue, SELENOP is able to incorporate selenium up to 10 selenocysteine residues within its primary structure. Two previous studies conducted in selenium-replete populations, one as a cross-sectional study (23) and the other as a selenium supplement trial (13) , investigated three selenium-related protein components in plasma including (i) SELENOP, (ii) GPX3 and (iii) non-specific protein components that do not contribute to SELENOP concentration or GPX3 activity. The first two components are found in the form of selenocysteine, and the last component is found as selenomethionine (35) . In both studies, non-specific protein components were more strongly correlated with selenium intake than the other two components (13, 23) . As our study only measured SELENOP, but not GPX3 or other selenium-related protein components in plasma, we were not able to determine whether other specific components might affect the risk of lung cancer. Among the many proteins such as catalase and glutathione peroxidase with antioxidant properties (36), our study focused on SELENOP. Hence, it is possible that other proteins may have a stronger influence on lung cancer risk than SELENOP, a possibility that needs to be investigated in future studies.
A strength of our study is the use of prospectively collected blood samples from a well-characterized, population-based cohort study of healthy middle-aged and elderly men. Our study included smoking status as a matching criterion, which minimizes the confounding by smoking more fully than previous studies that did not include smoking as a matching criterion (24, 25) . Our study also has limitations. Plasma SELENOP concentration may reflect a recent, but not long-term, intake of selenium intake and has not been established as a biomarker of selenium intake, especially in selenium-replete populations (21); rather, it may be more accurately viewed as a measure of functional selenium status (13, 23) . Given that potentially different etiologies have been reported for adenocarcinoma and squamous cell carcinoma lung cancer subtypes, it is possible that the association between SELENOP and lung cancer may differ by lung cancer subtypes. In our study, a limited number of cases had lung cancer histology information available, and our finding needs to be reevaluated when more lung cancer cases accrue, as well as in other study populations.
In summary, in our prospective study of adult Chinese men with adequate selenium status, we found little to support an inverse association between plasma SELENOP concentration and lung cancer risk. The possibility that an association exists, but that it differs by lung cancer subtype, is a potential explanation suggested by our findings that needs to be interpreted with caution and confirmed in future investigations.
